

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTORNEY DOCKET NO.	APPLICATION NO.
	APPLICANT Michael A. Adams, et al.	
	FILING DATE	GROUP

U. S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING D: IF APPROPRI
B.K.	AA	5,278,192	01/11/94	Fung et al.	514	645	
	AB	5,439,938	08/08/95	Snyder et al.	514	565	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI YES
	AL	WO 94/16729	4-Aug-94	WIPO			
	AM	WO 96/32118	17-Oct-96	WIPO			
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	AR	Linnet, Otto I. et al., "Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile Dysfunction," <i>New England Journal of Medicine</i> , 334(14):873-877 (1996).
	AS	Padma-Nathan, Harin et al., "Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil," <i>New England Journal of Medicine</i> 336(1):1-7 (1997).
↓	AT	Ferreira, Sérgio H. et al., "The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release," <i>European Journal of Pharmacology</i> 201:121-122 (1991).

EXAMINER

/Brian-Yong Kwon/

DATE CONSIDERED

06/08/2007

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT Michael A. Adams, et al.	
		FILING DATE	GROUP
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
B.K.	AU	Brock, Gerald et al., "Intracavernous Sodium Nitroprusside: Inappropriate Impotence Treatment," <i>Journal of Urology</i> 150:864-867 (1993).	
	AV	Duarte, I.D.G. et al., "Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway," <i>European Journal of Pharmacology</i> , 186:289-293 (1990).	
	AW	Ferreira, Sertgio H. et al., "Blockade of hyperalgesia and neurogenic oedema by topical application of nitroglycerin," <i>European Journal of Pharmacology</i> , 217:207-209 (1992).	
	AX	Duarte, Igor D.G. et al., "Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway," <i>European Journal of Pharmacology</i> , 217:225-227 (1992).	
	AY	Maurice, D.H. and Haslam, R.J. "Molecular Basis of the Synergistic Inhibition of Platelet Function by Nitrovasodilators and Activators of Adenylate Cyclase: Inhibition of Cyclic AMP Breakdown by Cyclic GMP," <i>Molecular Pharmacology</i> , 37(5):671-681 (1990).	
	AZ	Maurice, Donald H. et al., "Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle," <i>European Journal of Pharmacology</i> , 192:235-242 (1991).	
	AR2	Maurice, Donald H. and Haslam, Richard J., "Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle," <i>European Journal of Pharmacology</i> , 191:471-475 (1990).	
	AS2	Jang, Elliott K. et al., "Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: roles of cGMP and cAMP," <i>European Journal of Pharmacology</i> , 250:477-481 (1993).	
	AT2	von Heyden, Burkhard et al., "Intracavernous Pharmacotherapy for Impotence: Selection of Appropriate Agent and Dose," <i>Journal of Urology</i> , 149:1288-1290 (1993).	
	AU2	Hempelmann, Ralf, G. et al., "Non-synergistic relaxant effects of vasoactive intestinal polypeptide and SIN-1 in human isolated cavernous artery and corpus cavernosum," <i>European Journal of Pharmacology</i> 276:277-280 (1995).	
	AV2	Martinez-Pineiro, Luis et al., "Preliminary Results of a Comparative Study with Intracavernous Sodium Nitroprusside and Prostaglandin E1 in Patients with Erectile Dysfunction," <i>Journal of Urology</i> 153:1487-1490 (1995).	
	AW2	Sun,, Jim X. et al., "Comparative Pharmacokinetics and Bioavailability of Nitroglycerin and its Metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II Systems Using a Stable-Isotope Technique," <i>J. Clin. Pharmacol.</i> 35:390-397 (1995).	
EXAMINER		DATE CONSIDERED	
/Brian-Yong Kwon/		06/08/2007	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Michael A. Adams et al.
		Art Unit	1617
		Examiner Name	Wang, S.
Sheet 1 of 1	Attorney Docket Number		

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
B.K.	AA	Campbell et al., "Prevention of Tolerance to Nitroglycerin Patches by Overnight Removal," <i>Am J Cardiol</i> , 60:271-275 (1987)	
	AB	Parker, "Nitrate Tolerance," <i>Am J Cardiol</i> , 56:281-311 (1985)	
	AC	Packer et al., "Hemodynamic Factors Limiting the Response to Transdermal Nitroglycerin in Severe Chronic Congestive Heart Failure," <i>Am J Cardiol</i> , 57:260-267 (1986)	
	AD	Flaherty, "Hemodynamic Attenuation and the Nitrate-Free Interval: Alternative Dosing Strategies for Transdermal Nitroglycerin," <i>Am J Cardio</i> , 58:321-371 (1985)	
	AE	Armstrong et al., "Blood Levels After Sublingual Nitroglycerin," <i>Circulation</i> , 59(3):585 (1979)	
	AF	Nabel et al., "Effects of Dosing Intervals on the Development of Tolerance to High Dose Transdermal Nitroglycerin," <i>Am J Cardiol</i> , 63:663-669 (1989)	
	AG	Lin et al., "Crossover from Intravenous to Transdermal Nitroglycerin Therapy in Unstable Angina Pectoris," <i>Am J Cardiol</i> , 56:742-748 (1985)	

Examiner Signature	/Brian-Yong Kwon/	Date Considered	06/08/2007
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9054564 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	
Filing Date	
First Named Inventor	Adams et al.
Group Art Unit	1617
Examiner Name	Wang, S.
Attorney Docket Number	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
B.K.	AA	5877216		Place et al.	03/02/99	
B.K.	AB	6308841		Place et al.	10/23/01	
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AU							
	AV							
	AW							
	AX							
	AY							
	AZ							
	BA							

Examiner Signature	/Brian-Yong Kwon/	Date Considered	06/08/2007
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9036202 v1